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Research Article
PSYCHOTHERAPY VERSUS PHARMACOTHERAPY FOR
POSTTRAUMATIC STRESS DISORDER: SYSTEMIC
REVIEW AND META-ANALYSES TO DETERMINE
FIRST-LINE TREATMENTS
Daniel J. Lee, M.D.,1,2∗ Carla W. Schnitzlein, D.O.,2,3 Jonathan P. Wolf, M.D.,4 Meena Vythilingam, M.D.,5
Ann M. Rasmusson, M.D.,6,7,8 and Charles W. Hoge, M.D.9
Background:Current clinical practice guidelines (CPGs) for posttraumatic stress
disorder (PTSD) offer contradictory recommendations regarding use of medi-
cations or psychotherapy as first-line treatment. Direct head-to-head compar-
isons are lacking. Methods: Systemic review of Medline, EMBASE, PILOTS,
Cochrane Central Register of Controlled Trials, PsycINFO, and Global Health
Library was conducted without language restrictions. Randomized clinical trials
8 weeks in duration using structured clinical interview-based outcome mea-
sures, active-control conditions (e.g. supportive psychotherapy), and intent-to-
treat analysis were selected for analyses. Independent review, data abstraction,
and bias assessment were performed using standardized processes. Study out-
comes were grouped around conventional follow-up time periods (3, 6, and 9
months). Combined effect sizes were computed using meta-analyses for medica-
tion versus control, medication pre-/posttreatment, psychotherapy versus control,
and psychotherapy pre-/posttreatment. Results: Effect sizes for trauma-focused
psychotherapies (TFPs) versus active control conditions were greater than med-
ications versus placebo and other psychotherapies versus active controls. TFPs
resulted in greater sustained benefit over time than medications. Sertraline, ven-
lafaxine, and nefazodone outperformed other medications, although potential for
methodological biases were high. Improvement following paroxetine and fluox-
etine treatment was small. Venlafaxine and stress inoculation training (SIT)
demonstrated large initial effects that decreased over time. Bupropion, citalo-
pram, divalproex, mirtazapine, tiagabine, and topiramate failed to differenti-
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ate from placebo. Aripiprazole, divalproex, guanfacine, and olanzapine failed to
differentiate from placebo when combined with an antidepressant. Conclusions:
Study findings support use of TFPs over nontrauma-focused psychotherapy or
medication as first-line interventions. Second-line interventions include SIT,
and potentially sertraline or venlafaxine, rather than entire classes of medica-
tion, such as SSRIs. Future revisions of CPGs should prioritize studies that utilize
active controls over waitlist or treatment-as-usual conditions. Direct head-to-
head trials of TFPs versus sertraline or venlafaxine are needed. Depression and
Anxiety 33:792–806, 2016. C© 2016 Wiley Periodicals, Inc.
Key words: PTSD; posttraumatic stress disorder; pharmacotherapy; psychother-
apy; VA/DoD; ISTSS; NICE; WHO; Australian; Department of Defense; Inter-
national Society for the Study of Traumatic Stress; National Institute for Clinical
Excellence; World Health Organization
INTRODUCTION
Current clinical practice guidelines (CPGs) for post-
traumatic stress disorder (PTSD) offer contradictory
recommendations regarding use of medications or psy-
chotherapy as first-line treatment despite having ba-
sis in common clinical literature.[1–6] Veteran’s Af-
fairs/Department ofDefense (VA/DoD), American Psy-
chiatric Association (APA), and International Soci-
ety for Traumatic Stress Studies (ISTSS) guidelines
present medications and psychotherapy as equivalent
first-line treatments.[1,3, 6] Conversely, National Insti-
tute for Clinical Excellence (NICE), Australian, and
World Health Organization (WHO) assert trauma-
focused psychotherapies (TFPs) are superior to medica-
tions, and recommend against medication when TFPs
are available.[2,4, 5] Methodologically, VA/DoD, APA,
and ISTSS prioritize number of positive trials and
value uncontrolled data whereas other guidelines base
recommendations on larger effects for TFPs against
control.[1–6] Each guideline utilized different review
methodologies and inclusion/exclusion criteria for stud-
ies considered.[1–6]
Medication recommendations differ across guidelines
as well.[1–6] VA/DoD experts conclude all selective sero-
tonin reuptake inhibitors (SSRIs) and serotonin nore-
pinephrine reuptake inhibitors (SNRIs) are roughly
equivalent first-line treatments.[1] They advocate use of
prazosin, tricyclic antidepressants (TCAs), monoamine
oxidase inhibitors (MAO-Is), and nefazodone as second-
line interventions. ISTSS experts recommend sertra-
line, paroxetine, fluoxetine, venlafaxine, mirtazapine,
nefazodone, and prazosin for first-line use.[3] They
advocate second-line use of phenelzine, amitriptyline,
and bupropion. APA experts conclude SSRIs warrant
first-line use, with all other second-generation antide-
pressants comprising second-line use. NICE experts
find paroxetine, sertraline, amitriptyline, and phenelzine
superior to other medications for second-line use.[2]
Australian guidelines recommend SSRIs, and WHO
recommends TCAs and MAO-Is.[4–6] All recommend
against regular use of antiepileptics, antipsychotics, and
benzodiazepines.[1–6] One reason for differing guideline
recommendations is that psychotherapy effects are gen-
erally larger than those observed in medication studies.
However, many psychotherapy studies involve waitlist
and treatment-as-usual control conditions that inflate
effect sizes, and do not control for time with a provider
and other nonspecific treatment factors. Active-control
conditions in psychotherapy studies, and particularly
placebo-control inmedication trials, tend to narrow effi-
cacy margins between treatment and control conditions.
Discussion of PTSD psychotherapy is complicated
by the term trauma-focused cognitive behavioral ther-
apy (TF-CBT), which has two meanings. When used in
guidelines, TF-CBT generally encompasses both mean-
ings, and is synonymous with TFP, referring collectively
to all types of psychotherapy with trauma-focus, includ-
ing eye movement desensitization (EMDR), prolonged
exposure (PE), cognitive processing therapy (CPT),
imaginal exposure (IE), as well as a specific type of TFP
used in some studies.NICE,WHO,Australian, andAPA
guidelines recommend TFP/TF-CBTs as a group.[2,4–6]
VA/DoD guidelines recommend psychotherapy that in-
cludes components of exposure or cognitive restruc-
turing such as EMDR, PE, CPT, IE, TF-CBT, or
stress inoculation training (SIT). ISTSS guidelines
highlight EMDR, PE, CPT, and SIT as first-line
treatments.[3]
This series of meta-analyses was designed to answer
the primary question of whether TFPs are superior to
medications, or if both are generally equivalent first-
line interventions in adult populations with PTSD. Al-
though several recent expert reviews and meta-analyses
of PTSD treatment have been published, they have
methodological limitations, including unsystematic or
overly stringent inclusion/exclusion criteria or statisti-
cal extrapolations made from uncontrolled open-label
data.[7–12] Most, importantly, previous analyses were
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Figure 1. (A) Generic search strategy (interventions), (B) search strategy (syntax).
not designed to address the core question of whether
TFPs have greater evidence of effectiveness than medi-
cations. Our goal in this analysis was to provide rigorous,
transparent, and valid comparisons to inform clinical
practice and improve existing CPGs. We compare
medication and psychotherapy performance against
placebo- or active-control conditions, as well as pre-
/posttreatment symptom severity using gold-standard
PTSD outcome measures. Based on evidence reviews
in existing CPGs, we hypothesized that psychotherapy
would outperform medications under controlled condi-
tions, due to larger effect sizes observed in these studies,
but would have generally comparable within-group pre-
/posttreatment improvements,most strongly supporting
VA/DoD and ISTSS guideline recommendations.
METHODS
This report adheres to PRISMA guidelines.[13] Four authors (D.L.,
C.S., J.W., C.H.) searched Medline (1900-July 2015), EMBASE
(1860-July 2015), PILOTS, Cochrane Central Register of Controlled
Trials, PsycINFO (1806-July 2015), and Global Health Library with-
out language restrictions. Our full search strategy is online (Fig. 1A
and B). Search involved combinations of PTSD and generic medica-
tion names, psychotherapy names, and psychotherapy abbreviations.
Bibliographies of included studies and guidelines were reviewed for
citations to supplement the search.
We searched for published and unpublished randomized adult clin-
ical trials of any therapy or medication compared with active/placebo-
control conditions utilizing intention-to-treat analyses. We defined 8
weeks of medication or eight sessions of psychotherapy as the mini-
mum length necessary for inclusion, a broad definition often used in
health services research.[14] We included every medication for which
we could find qualifying studies. Psychotherapy sessions for both treat-
ment and control conditions were required to be individual, in-person,
manualized, and45 min in duration. The in-person criterion was re-
quired to avoid potentially confounding results due to differences in
nonspecific effects associated with direct interaction with the thera-
pist in the room. Group therapies were excluded due to their lim-
ited evidence, nonspecific social effects of the group environment, and
clinical challenges delivering core trauma-focused components in this
manner. Psychotherapies deviating from traditional manualized ap-
proaches were excluded. For this study, the term “TF-CBT” is used
only to refer to a specific psychotherapy type and TFPs refer to the
entire group of psychotherapies.
PTSD diagnosis using DSM-III-R or DSM-IV-TR criteria was
required prior to treatment initiation. PTSD trials with 100% preva-
lence of comorbid conditions, such as borderline personality disorder,
primary thought disorder, or substance use disorder were excluded as
these were not generalizable to standard patient populations. How-
ever, many studies included samples with high percentages of comor-
bid substance abuse, depression, and anxiety disorders at rates typical
of PTSD study populations. Gold standard, interview-based outcome
measures required for inclusion were Clinician-Administered PTSD
Scale (CAPS), Short PTSD Rating Interview (SPRINT), and PTSD
Depression and Anxiety
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Figure 1. Continued.
Symptom Scale-Interview (PSS-I), which have been validated against
the Structured Clinical Interview for DSM-IV and CAPS and widely
adopted in PTSD research. Outcome measures created for specific
RCTs or validated as part of an RCT design were excluded. These
included standardized interview for PTSD (SI-PTSD), revised stan-
dardized interview for PTSD (SIP), and several outcome measures
named for Duke University.[15–18]
Study outcomes were grouped by follow-up duration (8–12 weeks,
14–27weeks, and 32+weeks) and consolidated into overall effect using
meta-analysis. Our intent was to separate outcome measures into tra-
ditional 3-, 6-, and 9-month end points as a surrogate for performance
over time. Selected ranges allowed for capture of outcome measure-
ments occurring at or closely around these time points. Outcomes
beyond 32 weeks were grouped together due to variable end points.
Many medication trials longer than 12 weeks involved maintenance
(continuing medication after response) and relapse prevention (deter-
mining if switch to placebo after response causes loss of efficacy). Both
designs were retained because they began from similar baselines and
their exclusion would have eliminated most long-term medication tri-
als. Although most psychotherapy trials involved weekly treatment, if
treatment was provided more or less frequently, outcomes collected
immediately posttreatment were included within the 8- to 12-week
grouping. Later measures were grouped normally.
Given the paucity of psychotherapy studies that excluded concomi-
tantmedications, we allowed psychotherapy trials inwhich participants
were taking medications, provided these were similar for treatment
and control. All included medication studies involved placebo control.
Medication studies wherein >25% of the study population was main-
tained on an antidepressant were considered adjunctive trials as they
differed significantly from monoagent trials requiring discontinuation
of all other medications. Psychotherapy controls included support-
ive psychotherapy, biofeedback, and relaxation training. Waitlist and
treatment-as-usual controls were deemed insufficient to account for
nonspecific treatment effects and were excluded.
Depression and Anxiety
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For studies meeting above inclusion criteria, we avoided exclusions
based on study quality or risk of bias, since differing inclusion/exclusion
criteria appeared to be a major factor in variation between guideline
recommendations. Most importantly, exclusion of studies deemed at
high risk of bias would have resulted in exclusion of most medica-
tion trials; we prioritized answering our research question, even if this
meant inclusion of biased studies.
STUDY SELECTION AND DATA ABSTRACTION
We utilized a two-stage study selection process. In stage one, four
authors (D.L., C.S., J.W., C.H.) independently reviewed titles and
abstracts to select full text articles. If based on abstract or title, a
study was determined to be randomized, but study length or session
number could not be determined (or vice versa), we erred toward re-
trieval. If neither could be determined, it was excluded. During stage
two, D.L. and C.S., J.W., M.V., A.R., or C.H. independently applied
inclusion/exclusion criteria using standardized forms, assessed article
quality using Cochrane’s bias assessment tool,[19] and extracted data.
Interrater agreement was high for these measures (>95%). Disagree-
ments centered on handling of unanticipated outcome measures and
psychotherapy controls and were resolved by consensus. Extracted de-
mographic information appears in Table 1.
STATISTICAL ANALYSIS
Meta-regression was considered, but rejected in favor of meta-
analysis, which was deemed more accurate for nonlinear data and time
intervals driven by clinical convention. Due to differences between
CAPS, SPRINT, and PSS-I, we computed study effect sizes to de-
termine overall effect size for each intervention. By convention, effect
sizes greater than 0.8 are considered large, those between 0.6 and 0.8
moderate, and those between 0.2 and 0.5 small.[20] Performance ver-
sus control was computed using treatment and control measures taken
at the same time. Pre-/posttreatment analyses compared treatment
group measures against group baseline. Guideline comparisons were
done by combining effects for all first-line or second-line interventions
recommended in the guidelines using meta-analysis. For example, the
VA/DoD guideline recommends SSRIs and SNRIs as first-line phar-
macological treatments, and TFT or SIT as first-line psychotherapies.
Thus, we ran separate meta-analyses involving the various combina-
tions of studies using these different first-line treatments.
Studies analyzing different aspects of the same study population
were combined into a single study for analysis. Studies with multi-
ple treatment arms measured against a single active-control condition
were analyzed as separate studies (e.g., PE vs. interpersonal therapy
(IPT) vs. control became PE vs. control and IPT vs. control). All un-
controlled data points were excluded.Data points were excluded if they
involved exclusion of treatment responders or treatment nonrespon-
ders. Heterogeneity was assessed using the I2 statistic, though large
heterogeneity was expected due to inclusion of many interventions
(Fig. 2).[21] We estimated number of unpublished trials needed to in-
validate our findings using file drawer/fail safe (FDFS).[22] All analyses
were completed using Stata’s metan command (v.11). Meta-analyses
utilized inverse variance weighting with random effects.
RESULTS
Of 61,268 initial search results, 285 potential arti-
cles were identified, retrieved, and assessed for eligibil-
ity (Fig. 3). Sixty-three articles met inclusion criteria;
seven of these articles[23–29] described outcomes from
three research populations. These results were com-
bined into three studies, leaving 58 independent stud-
ies. Three studies replicated data from other included
studies, leaving 55 total studies. Interventions that met
inclusion criteria and number of studies using them in-
cluded aripiprazole (1),[30] brofaromine (2),[31,32] bupro-
pion (1),[33] TF-CBT (2),[23,24,34] citalopram (1),[35] CPT
(1),[36] divalproex (2),[37,38] EMDR (2),[39,40] fluoxetine
(5),[25,26,41–44] guanfacine (2),[45,46] IPT (1),[47] mirtaza-
pine (1),[16] nefazodone (1),[48] olanzapine (3),[18,49,50]
paroxetine (7),[51–57] PE with cognitive restructuring
(PE/CR) (2),[58,59] PE (7),[40,47,58–62] prazosin (3),[63–65]
risperidone (5),[66–70] sertraline (5),[27–29,35,71–73] SIT
(1),[60] tiagabine (2),[17,74] topiramate (2),[75,76] and ven-
lafaxine (2).[71,77]
A total of 6,313 participants were enrolled across all
trials (Table 1). Average study duration was 18 weeks
(range 8–104) with the average medication study run-
ning 17 weeks (8–64) and the average psychotherapy
study running ten sessions (8–12). A mean of 115 partic-
ipants (10–551) took part in each study. Forty-nine per-
cent of participants were women (0–100%).Mean age of
participants was 42 (30–55). All included studies were in
English. Thirty-onemedication trials (72%)were indus-
try supported. Average percentage of veterans was 40%
(0–100%). Dropout average was 29% (0–79%). In 36
studies specifying major depressive disorder prevalence
at initiation, average comorbidity was 41% (0–86%).
QUALITY AND RISK OF BIAS
Quality varied, with most studies having important
limitations in design, reporting, or both (Table 2).
Double-blinding was not possible for psychotherapy
studies, and it is unlikely nonspecific placebo effects
were fully controlled for, even with optimal methods.
Nevertheless, psychotherapy trials were generally better
designed, executed, and reported than medication
studies. Cochrane criteria demonstrated considerable
differences in risk of bias between medication and
psychotherapy studies (Table 2). Most psychother-
apy trials were rated low or very low risk of bias
and most medication trials were rated high or very
high risk of bias, despite the fact they were placebo
controlled. Differences were noted for allocation
concealment, adherence, sequence generation, and
industry sponsorship, suggesting fundamental de-
sign and reporting differences. A typical medication
study was conducted by one of a handful of industry-
sponsored researchers, selectively reported data, and
failed to disclose methods for randomization, alloca-
tion concealment, or adherence. Failure to perform
pill counts, having treating providers assess outcome
measures, and nonrandom group assignments allowed
possible influence toward desired outcomes. Random-
ization and blinding success were also questionable
in some medication studies with groups differing
significantly in adverse effects and attrition, which
could easily jeopardize allocation concealment. Data
reporting, standardized across psychotherapy studies,
varied across medication studies, particularly among
industry-sponsored trials. Most medication studies and
Depression and Anxiety
Research Article: Comparison of PTSD Guidelines 797
TABLE 1. Demographic information for included studies
Author Mean dose/
Intervention (year) N Veterans (%) Women (%) Mean age Depression % No. of sessions
Aripiprazole Naylor (2015) 16 100 31 34 86 10 mg
Brofaromine Baker (1995) 118 60 19 44 Uncertain Uncertain
Brofaromine Katz (1995) 45 18 24 39 0 Uncertain
Bupropion Becker (2007) 28 50 21 50 Uncertain 300 mg
CPT Suris (2013) 86 0 85 46 Uncertain 10 sessions
Divalproex Davis (2008) 85 100 Uncertain 55 Uncertain 2309 mg
Divalproex Hamner (2009) 29 100 3 52 69 1196 mg
EMDR Carlson (1998) 35 100 0 48 Uncertain Uncertain
EMDR, PE, PE/CR Taylor (2003) 60 0 75 37 42 8 sessions
Fluoxetine Davidson (2005) 123 32 50 44 Uncertain 49 mg
Fluoxetine Martenyi (2007) 411 5 72 41 Uncertain 30 mg
Fluoxetine Martenyi (2002),
Martenyi (2002)
301 31 19 38 0 57 mg
Fluoxetine Martenyi (2006) 144 100 1 36 0 65 mg
Fluoxetine van der Kolk (2007) 59 0 83 36 Uncertain 30 mg
Guanfacine Davis (2008) 35 100 6 53 57 2 mg
Guanfacine Neylan (2006) 56 100 Uncertain Uncertain Uncertain 2 mg
IE, IE/CR Bryant (2003) 58 0 52 35 Uncertain Uncertain
Mirtazapine Davidson (2003) 29 14 50 47 73 39 mg
Nefazodone Davis (2004) 41 98 2 54 39 435 mg
Olanzapine Butterfield (2001) 15 60 93 43 53 14 mg
Olanzapine Carey (2012) 28 0 61 41 0 9 mg
Olanzapine Stein (2002) 21 100 0 53 Uncertain 15 mg
Paroxetine GlaxoSmithKline (2001) 263 0 66 43 0 Uncertain
Paroxetine Marshall (2001) 551 8 67 42 45 30 mg
Paroxetine Marshall (2007) 52 0 67 40 63 Uncertain
Paroxetine Schneier (2012) 37 0 54 50 66* 32 mg
Paroxetine Tucker (2000) 323 7 66 41 35 28 mg
Paroxetine Fani (2009) 18 Uncertain 56 41 Uncertain Uncertain
Paroxetine Fani (2011) 13 8 54 40 85 Uncertain
PE Schnurr (2007) 284 100 100 45 64* 9 sessions
PE Rauch (2014) 30 100 8 32 47 11 sessions
PE, IPT Markowitz (2015) 110 0 77 40 50 8 PE/13 IPT
PE, PE/CR Marks (1998) 87 3 36 38 49 Uncertain
PE, SIT Foa (1991) 45 0 100 32 Uncertain Uncertain
Prazosin Raskind (2007) 38 100 5 56 Uncertain 13 mg
Prazosin Raskind (2013) 67 100 15 30 34 20 mg men / 9 mg
women
Prazosin Raskind (2003) 10 100 0 53 Uncertain 10 mg
Risperidone Padala (2006) 20 0 100 41 Uncertain 3 mg
Risperidone Reich (2004) 21 0 100 28 62 1 mg
Risperidone Bartzokis (2004) 65 100 0 52 Uncertain 3 mg
Risperidone Krystal (2011) 296 100 3 54 70 3 mg
Risperidone Rothbaum (2008) 20 0 80 34 80 2 mg
Sertraline Brady (2000), Davidson
(2001), Davidson
(2001)
385 5 76 38 37 139 mg
Sertraline Friedman (2007) 169 100 20 46 0 135 mg
Sertraline Zohar (2002) 42 100 12 40 0 120 mg
Sertraline, citalopram Tucker (2003) 58 3 74 39 78 Sert 134 mg/cit 36 mg
Sertraline, venlafaxine Davidson (2006) 531 9 Uncertain Uncertain 0 Sert 110 mg/ven 164 mg
TF-CBT Blanchard (2003),
Blanchard (2003)
98 0 73 40 49 10 sessions
TF-CBT McDonaugh (2005) 74 0 100 40 Uncertain Uncertain
TF-CBT Ehlers (2014) 121 0 59 39 36 12 sessions
Tiagabine Connor (2005) 26 4 73 41 Uncertain 11 mg
Tiagabine Davidson (2007) 232 9 66 43 38 11 mg
Topiramate Tucker (2007) 40 0 79 42 61 150 mg
Topiramate Yeh (2011) 35 0 68 40 13 103 mg
Venlafaxine Davidson (2006) 329 12 54 41 0 182 mg
CPT, cognitive processing therapy; EMDR, eye movement desensitization reprocessing therapy; IE, imaginal exposure; PE, prolonged exposure;
PE/CR, prolonged exposure with cognitive restructuring; SIT, stress inoculation training; TF-CBT, trauma-focused cognitive behavioral therapy.
∗Reporting of mood disorder rather than depression.
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Figure 2. I2 statistic.
several psychotherapy studies reported outcome data
selectively or in a misleading manner. Examples in-
cluded partial/nonstandard reporting between text and
charts,[19,20,22–27,32–35,37–39,42,44–46,49,52,56,58,60,62,63,65–69]
switching between mean/mean
change,[25,26,38,43–45,48,50,52,66,69,71–75] switching be-
tween standard deviations(SD)/confidence inter-
vals/standard errors,[25,26,28,30,43,44,51,55,62,64,67,71,72]
omitting baseline outcome data,[28,33,68] omitting vari-
ance measures completely,[28,31,68] omitting outcome
measures at specific time points,[28,40,68] creation of
nonstandard outcome measures by combining standard
measures with other variables,[25,28,32,41,44,51,73] splitting
outcomemeasures into subscales without providing total
score,[39,58] failure to cross-reference data spread over
several publications,[25,26,43,44] and including nonscaled
graphs without providing corresponding means.[28,40,68]
Data abstraction for most medication studies required
mathematical conversion of provided data into mean to-
tal CAPS/SPRINT/PSS-I and SD. Data extraction for
Figure 3. Flow of Studies, Reasons for nonretrieval or exclusion involved one or more of the following: (1) not pertinent to research
question, (2) duration was too short, (c) wrong outcome measure(s), and/or (d) study involved acute stress disorder or subdiagnostic
PTSD.
Depression and Anxiety
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TABLE 2. Application of Cochrane bias assessment to all included studies
Author Dropout Sequence Allocation Industry Selective
Bias risk Intervention (year) (%) Adherence generation concealment support reporting
Very low CPT Suris (2013) 28 Yes Yes Yes No No
Very low IE, IE/CR Bryant (2003) 22 Yes Yes Yes No No
Very low PE, PE/CR Marks (1998) 60 Yes Yes Yes No Yes
Very low PE Schnurr (2007) 29 Yes Yes Yes No No
Very low PE Markowitz (2015) 25 Yes Yes Yes No No
Very low TF-CBT Ehlers (2014) 3 Yes Yes Yes No No
Very low Topiramate Yen (2011) 26 Yes Yes Yes No No
Low TF-CBT Blanchard (2003),
Blanchard (2003)
20 Yes Uncertain Yes No Yes
Low TF-CBT McDonaugh (2005) 23 Yes Uncertain Yes No Yes
Low EMDR Carlson (1598) 3 Yes Uncertain Yes No Yes
Low EMDR, PE Taylor (2003) 35 Yes Uncertain Yes No Yes
Low Fluoxetine Martenyi (2002),
Martenyi (2002)
61 Yes Yes Yes Yes No
Low Fluoxetine Martenyi (2005) 67 No Yes Yes No Yes
Low PE, SIT Foa (1991) 18 Yes Uncertain Yes No Yes
Low Prazosin Raskind (2007) 18 Uncertain Yes Yes No Yes
Low Divalproex Davis (2008) 20 Uncertain Yes Yes No Yes
Moderate Fluoxetine van der Kolk (2007) 34 Uncertain Uncertain Yes No Yes
Moderate Paroxetine Schneier (2012) 41 Uncertain Uncertain Yes No Yes
Moderate PE Rauch (2014) 28 Uncertain Uncertain Yes No Yes
Moderate Divalproex Hamner(2009) 48 Yes Uncertain Yes Yes Yes
Moderate Guanfacine Neylan (2006) 10 Yes Uncertain Yes No Yes
High Brofaromine Baker (1995) 30 Uncertain Uncertain Uncertain Yes Yes
High Brofaromine Katz (1995) 27 Uncertain Uncertain Uncertain Yes Yes
High Bupropion Becker (2007) 23 Uncertain Uncertain Uncertain Yes Yes
High Fluoxetine Davidson (2005) 44 Yes Uncertain Uncertain Yes Yes
High Mirtazapine Davidson (2003) 31 Uncertain Uncertain Uncertain No Yes
High Nefazodone Davis (2004) 44 Uncertain Uncertain Yes Yes Yes
High Paroxetine Marshall (2007) 42 Uncertain Uncertain Yes Yes Yes
High Prazosin Raskind (2013) 39 Uncertain Uncertain Uncertain No Yes
High Prazosin Raskind (2003) 0 Uncertain Uncertain Uncertain No Yes
High Sertraline Brady (2000), Davidson
(2001), Davidson
(2001)
79 Yes Uncertain Uncertain Yes Yes
High Sertraline Friedman (2007) 24 Uncertain Yes Uncertain Yes Yes
High Sertraline Zohar (2002) 26 Yes Uncertain Uncertain Yes Yes
High Olanzapine Carey (2012) 29 Uncertain Yes Uncertain Yes Yes
High Topiramate Tucker (2007) 5 Uncertain Yes Uncertain Yes Yes
High Aripiprazole Naylor (2015) 25 Uncertain Uncertain Uncertain No Yes
High Guanfacine Davis (2008) 19 Uncertain Uncertain Uncertain No Yes
Very high Fluoxetine Martenyi (2007) 12 Uncertain Uncertain Uncertain Yes Yes
Very high Paroxetine GlaxoSmithKline (2001) 51 Uncertain Uncertain Uncertain Yes Yes
Very high Paroxetine Marshall (2001) 37 Uncertain Uncertain Uncertain Yes Yes
Very high Paroxetine Tucker (2000) 39 Uncertain Uncertain Uncertain Yes Yes
Very high Sertraline, Citalopram Tucker (2003) 24 Uncertain Uncertain Uncertain Yes Yes
Very high Sertraline, Venlafaxine Davidson (2006) 34 Uncertain Uncertain Uncertain Yes Yes
Very high Venlafaxine Davidson (2006) 32 Uncertain Uncertain Uncertain Yes Yes
Very high Olanzapine Butterfield (2001) 27 Uncertain Uncertain Uncertain Yes Yes
Very high Tiagabine Connor (2005) 50 Uncertain Uncertain Uncertain Yes Yes
Very high Tiagabine Davidson (2007) 61 Uncertain Uncertain Uncertain Yes Yes
Very high Paroxetine Fani (2009) 44 Uncertain Uncertain Uncertain Yes Yes
Very high Paroxetine Fani (2011) 0 Insufficient Uncertain Uncertain Yes Yes
Very high Risperidone Padala (2006) 0 Uncertain Uncertain Uncertain Yes Yes
Very high Risperidone Reich (2004) 0 Uncertain Uncertain Uncertain Yes Yes
Very high Olanzapine Stein (2002) 10 Uncertain Uncertain Uncertain Yes Yes
Very high Risperidone Bartzokis (2004) 26 Uncertain Uncertain Uncertain Yes Yes
Very high Risperidone Krystal (2011) 17 Uncertain Uncertain Uncertain Yes Yes
Very high Risperidone Rothbaum (2008) 44 Uncertain Uncertain Uncertain Yes Yes
CPT, cognitive processing therapy; EMDR, eye movement desensitization reprocessing therapy; IE, imaginal exposure; PE, prolonged exposure;
PE/CR, prolonged exposure with cognitive restructuring; SIT, stress inoculation training; TF-CBT, trauma-focused cognitive behavioral therapy.
All trials with ITT design. All therapy trials unblinded and all medication trials were blinded.
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two studies[28,68] were particularly problematic; neither
mean total CAPS nor baseline total CAPS were pro-
vided. Each required us to estimate CAPS and variance
from a nonscaled graph. Several attempts to obtain data
from Pfizer and Janssen were unsuccessful, forcing us
to use our best estimate. Request for the second neg-
ative Pfizer study submitted to the FDA in support of
a PTSD indication for sertraline was also unsuccess-
ful. Psychotherapy data requests, in contrast, were re-
turned promptly. Estimates based on FDFS suggested
that 12,581 unpublished trials with no effect would be
required to reduce controlled findings to statistical in-
significance and 51,639 would be required to invalidate
pre-/posttreatment findings.
EFFICACY TRENDS
Pre-/Posteffects for Monoagent Pharmacother-
apy and Psychotherapy. Pre-/post comparisons
across treatments demonstrated large effects for both
medications and psychotherapy, which generally in-
creased over time when follow-up data were included
(Tables 3 and 4). Pre-/posteffect sizes for TFPs were
larger than individual medications and medication
groupings (i.e. SSRIs), and was particularly notable
9 months or more after psychotherapy was initiated.
Most adjunctive pharmacotherapy studies failed to show
benefit.
Efficacy ofMonoagent Pharmacotherapy and Psy-
chotherapy versus Controls. When compared with
control, effect sizes were uniformly lower than those
observed in pre-/postcomparisons. TFPs clearly out-
performed individual and medication groupings and
nontrauma-focused psychotherapies (non-TFPs) across
the diverse group of psychotherapies including PE/IE,
PE/CR, CPT, EMDR, and TF-CBT (Tables 3 and 4).
PE/IE demonstrated the most consistent effects across
time. Addition of cognitive techniques to PE appeared to
make it less effective, although outcomes at final follow-
up were consistent with PE alone. CPT and TF-CBT
also demonstrated moderate-to-large effect sizes across
time. EMDR demonstrated an effect size comparable
to other trauma-focused therapies, but failed to reach
significance at the final time-point, likely due to be-
ing underpowered. SIT demonstrated large initial effect
with diminishing effects beyond 12 weeks. IPT never
achieved significance versus active-control condition.
Medications demonstrating large effects were sertraline,
venlafaxine, and nefazodone.
Brofaromine, bupropion, citalopram, monoagent
and adjunctive divalproex, mirtazapine, risperidone,
tiagabine, topiramate, adjunctive aripiprazole, adjunc-
tive guanfacine, and adjunctive olanzapine never
achieved significance against control. Paroxetine and
fluoxetine both performed poorly against control.
Antiepileptics as a class failed to achieve significance.
Antipsychotics as a class demonstrated small effects, but
this conclusion is limited by the myriad of side effects
and high risk of study bias.
Adjunctive Pharmacotherapy. Prazosin was the
only medication to demonstrate large effect and only at
14–27 weeks.
Comparison of Guidelines. When studies were
grouped by guideline recommendations for first and
second-line interventions, guidelines considering psy-
chotherapy superior to medications (Australian, WHO,
NICE) outperformed guidelines considering psy-
chotherapy and medications equivalent (ISTSS, APA,
VA/DoD) (Table 4). Guidelines recommending both
demonstrated lower effects than those restricting first-
line interventions to TFPs. ISTSS, APA, and VA/DoD
guideline recommendations performed similarly, with
the exception of ISTSS recommendations showing
larger effects at 14–27 weeks due to inclusion of pra-
zosin as a first-line intervention. Second-line interven-
tions performed poorly across all guidelines.
DISCUSSION
This is the most comprehensive set of meta-analyses
comparing psychotherapy and medication efficacy for
PTSD, and determining which specific treatments war-
rant first-line recommendations. Only psychotherapy
trials involving active-control conditions were included,
mirroring as closely as possible placebo-control condi-
tions used in medication trials.
By every measure considered in this study, TFPs
were superior to medications. In general, large reduc-
tions in gold-standard outcomes persisted long after
psychotherapy completion, whereas continued use of
medication was necessary for long-term benefits. These
findings are further strengthened considering the re-
quirement for active-control conditions and many ad-
vantages medication studies had in participant enroll-
ment, industry involvement and funding, and likelihood
of bias towardmore positive outcomes inmedication tri-
als (e.g. methodological bias or prioritizing recruitment
of patients with lower comorbidities or less prior treat-
ment). Our findings suggest that medications largely act
by blunting expression of symptoms of PTSD, rather
than acting on critical neurobiological mechanisms un-
derlying, for example, extinction of conditioned fear
responses, which is a primary target of exposure and
cognitive-based TFPs.
Concerning guideline recommendations, our findings
suggest PTSD treatment guidelines need revision. Clin-
icians should be educated on the priority of TFPs, and
many changes are required in medication recommenda-
tions. For example, our findings suggest patients who
experience partial responses to medication treatment
should be referred for TFP rather than being prescribed
a second medication. Superiority of the broad class of
TFPs over SIT or IPT suggests working directly with
trauma in some form leads to better outcomes, although
this conclusion is limited by the fact that only two stud-
ies directly compared non-TFPs with another active-
control condition. For individuals too avoidant or auto-
nomically activated to engage inTFP, SIT, sertraline, or
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venlafaxine appeared to be the most viable alternatives,
with caveats noted below.
Ourfindings contradict conventionalwisdomandpre-
scribing patterns, particularly in the United States. Our
analysis demonstrated psychotherapy and medication
are not equivalent, and not all SSRIs or SNRIs are
alike. Our study provides strong evidence against the
theory that PTSD involves a seizure-like kindling phe-
nomenon; antiepileptics were noneffective. Our study
also provides evidence against common U.S. practice of
utilizing antipsychotics in PTSD treatment.
Concerning second-line interventions, our finding
that sertraline, venlafaxine, and nefazodone outper-
formed other medication treatments comes with impor-
tant caveats. Although sertraline appeared to gain effi-
cacy compared with control over time, this finding was
driven by a single industry sponsored trial with selec-
tively reported data and high risk of bias.[28] Pfizer did
not provide data from a second sertraline trial that was
negative. Although venlafaxine demonstrated a large ini-
tial effect, this appeared to diminish beyond 12 weeks.
Nefazodone performed strongly in the short term, but
incurs the risk of liver failure.
Adjunctive medication treatment showed lack of effi-
cacy, with the exception of prazosin. However, this find-
ing is driven by studies from a single research group
with irregular study endpoints (15 and 20 weeks).[63,64]
Furthermore, a recent large multicenter trial of prazosin
failed to differentiate from placebo in the primary global
change score outcome, and PTSD-specific outcomes
have still not been published 3 years since completion of
recruitment.[78] Most adjunctive trials, including the pra-
zosin studies, involved treatment-resistant PTSD,which
is a population on which little research has been done.
It is possible that individuals with treatment-resistant
PTSD fundamentally differ from those participating in
most of our included research studies, although this is
currently unclear.
STRENGTHS AND LIMITATIONS
Strengths of this study include the methodological
rigor in data abstraction and analyses and presenta-
tion of data simultaneously for controlled and pre-
/posttreatment effects. We believe excluding medica-
tion trials without placebo-controls and psychotherapy
studies relying on waitlist or treatment-as-usual controls
was critically important in addressing our primary scien-
tific question, although this reduced analyzable studies.
Limitations included relatively few medication studies
extending beyond 12 weeks (reducing analyzable long-
term data), few psychotherapy studies running eight or
more sessions using active-control conditions and gold-
standard outcomemeasurements (many studies were ex-
cluded), small sample sizes in many studies (widening
confidence intervals), differing study designs (increasing
heterogeneity), and fundamental differences in bias be-
tween medication and psychotherapy studies.
Other limitations included concomitant use of psy-
chotropics in some medication and psychotherapy stud-
ies, and incomplete or misleading reporting of data.
Concomitant psychotropics could not be controlled for
as they were present in nearly every study analyzed.
There are also limitations in generalizing clinical tri-
als data to normative clinical populations, in part be-
cause selection of study participants is unable to fully
account the stepped manner in which PTSD treatments
are often utilized.[79] The high rate of prior psychotropic
treatment in many clinical trials, for example, could re-
flect a select subset of the PTSD population that has al-
ready received some degree of medical stabilization that
has prepared them for engagement in trauma-focused
psychotherapy.[79] However, since disease chronicity is
lower and proportion of treatment naı¨ve patients higher
in industry-sponsored pharmacotherapy trials compared
with psychotherapy trials, one would expect biases in the
direction favoring medications, rather than the results
we observed. Although not systematically analyzed, psy-
chotherapy interventions appeared to outperformmedi-
cations overall for both treatment naı¨ve samples aswell as
samples with high rates of prior or current psychotropic
treatment.
Our decision to group studies by time may have in-
troduced bias into our analysis, although this is unlikely.
A small correlation effect was introduced by using the
same control group twice for themultiarmed studies; this
method did not impact results as overall data remained
unchanged when individual arms or the entire study was
excluded. Each study demonstrated its own idiosyncratic
inclusion and exclusion criteria, which resulted in un-
avoidable differences in study populations. Comorbidi-
ties, previous treatment, and rates of substance abuse
varied. Analyzing these studies as a group presumably
minimizes the impact of individual differences. PTSD
symptom duration was not reported by most studies and
could not be analyzed. Outcome measure standardiza-
tion resulted in different treatment conclusions for some
studies than reported by their authors.
Although these analyses represent the highest level
of evidence available for medications, they should not
be used to compare effect sizes between different TFPs
due to exclusion of psychotherapy trials without active-
control conditions, including several important trials
that compared different TFPs head-to-head. The very
large pre-/posteffects for CPT in thismeta-analysis were
driven by a single study,[36] and the mildly inferior per-
formance of TF-CBT and EMDR compared with other
TFPs is likely an artifact of inclusion/exclusion crite-
ria and small samples. Individual TFPs have generally
been found equivalent in head-to-head trials. Due to
our study design, we cannot make recommendations
for individual TFPs or comment on individual versus
group TFP; these remain areas for further study. Addi-
tionally, these analyses standardized comparisons across
studies using mean effects, and recommendations do
not fully address heterogeneity of underlying patho-
physiological mechanisms contributing to differences
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in individual risk, severity, chronicity, or response to
treatment.
CONCLUSIONS
For future research, greater rigor and consistency in
design and reporting of outcomes is necessary across
studies to prevent biases. Medication trials, in particular,
would benefit from rigorous head-to-head comparisons
against FDA-indicated medications such as sertraline or
paroxetine, orTFPs, in addition to placebo comparisons.
Reduction in the influence of industry sponsorship is
critical. Well-controlled head-to-head studies of TFPs
versus medication are needed, as are studies of combi-
nations of TFP with sertraline or venlafaxine or other
medications that could potentially facilitate efficacy of
TFPs in relatively refractory patients.
Our findings contradict several aspects of VA/DoD,
NICE, ISTSS, WHO, Australian, and APA CPGs for
treatment of PTSD, and suggest a need for reconsid-
eration of current guideline recommendations. Guide-
lines could be improved by focusing on TFPs as the
preferred first-line intervention, with sertraline and ven-
lafaxine taking an adjunctive or secondary role. Guide-
lines should also begin discouraging use of polyphar-
macy for PTSD. Future research should focus on ways
of tailoring treatment to individual patients to improve
response and retention rates.
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